Switzerland· 68199002
Qinlock 50 mg, Tabletten
A ripretinib product containing ripretinibum, registered in Switzerland by Deciphera Pharmaceuticals (Schweiz) AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Ripretinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX19 (ripretinib), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Ripretinib · ATC L01EX19
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ripretinib costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.72 in France to $744.16 in Switzerland — a ×1040 gap.
- Switzerland: $744.16 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Ripretinib · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$744.16
- FR France$0.72
The record
At a glance
Swissmedic (Switzerland)- Active substance
- ripretinibum
- Manufacturer
- Deciphera Pharmaceuticals (Schweiz) AG
- Country
- Switzerland (CH)
- ATC code
- L01EX19
- ATC class
- Ripretinib
- Defined daily dose
- 0.15 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680681990024Fl 90 StkCHF 18514.6
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
133 interactions on record for ripretinib.
Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ripretinib · interactions on record
133 records
- 12 severe
- 121 moderate
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Darunavir and cobicistatJ05AR14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ripretinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaQINLOCKDeciphera Pharmaceuticals (Netherlands) B.V., Amsterdam
- SpainQINLOCK 50 MG COMPRIMIDOSDeciphera Pharmaceuticals (Netherlands) B.V.
- FinlandQINLOCKDeciphera Pharmaceuticals (Netherlands) B.V.
- FranceQINLOCK 50 mg, compriméDECIPHERA PHARMACEUTICALS (NETHERLANDS) (PAYS-BAS)
- United KingdomQinlock 50mg tabletsDeciphera Pharmaceuticals (Netherlands) B.V.
- IrelandQINLOCK 50 mg tabletsDeciphera Pharmaceuticals (Netherlands) B.V.
- IcelandQinlockDeciphera Pharmaceuticals (Netherlands) B.V.
- NetherlandsQinlock 50 mg tablettenDeciphera Pharmaceuticals (Netherlands) B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Qinlock
- Liechtenstein · Qinlock
- Norway · Qinlock
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c50a05ae-aa26-441f-9ee6-66ad806d36bb GET /v1/drugs/c50a05ae-aa26-441f-9ee6-66ad806d36bb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "ripretinibum 50 mg",
"valid_from": "2024-12-01",
"limitations": "[{\"description\":\"QINLOCK ist in einer Dosierung von maximal 150 mg einmal täglich zur Behandlung von erwachsenen Patienten mit fortgeschrittenen gastrointestinalen Stromatumoren (GIST), die mindestens 3 vorherige Therapien mit Kinaseinhibitoren, darunter Imatinib, Sunitinib und Regorafenib, erhalten haben, angezeigt. Die Patienten müssen eine adäquate Organfunktion und Knochenmarksreserve aufweisen.<br>\\nDie Verordnung von QINLOCK darf ausschliesslich durch einen Facharzt für Onkologie mit Erfahrung in der Behandlung von GIST erfolgen. QINLOCK darf nicht mit anderen onkologischen Therapien kombiniert werden. Die Behandlung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nDie Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung QINLOCK einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21521.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21521.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-12-01\",\"validTo\":\"2026-11-30\"}]",
"galenic_form": "Tabl 50 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2024-12-01",
"self_retention_pct": 10
}See everything about ripretinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.